Bill > H0530

This bill establishes new provisions for health benefit plans in Idaho concerning anticancer medications, defining an "anticancer medication" as any drug or biologic used to fight cancer, regardless of how it's administered (oral, intravenous, or injection). A "health benefit plan" refers to insurance plans as defined elsewhere in Idaho law. The key provision requires that if a health benefit plan covers Food and Drug Administration-approved anticancer medications, it must ensure that the patient's out-of-pocket costs for orally administered anticancer drugs are no more expensive than for injected or intravenously administered ones, either by having equal copayments, deductibles, or coinsurance, or by capping the out-of-pocket cost for a 30-day supply of oral anticancer medication at $250. The bill clarifies that plans are not required to classify these medications as a medical benefit, and that compliance will be measured by ensuring these cost protections are not undermined by increasing other patient costs or reclassifying benefits. The bill also declares an emergency and sets an effective date of July 1, 2026.

Business and Industry

Health and Welfare Committee (House)

https://legislature.idaho.gov/sessioninfo/2026/legislation/H0530/